Fresenius Medical Care Q1 Earnings Preview
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy FMS?
Source: seekingalpha
- Earnings Announcement Date: Fresenius Medical Care is set to announce its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at €0.59, reflecting a significant 29.8% year-over-year decline, which could impact investor sentiment.
- Revenue Expectations: The revenue estimate for Q1 stands at €5.42 billion, representing an 11.0% year-over-year increase, indicating resilience in the company's market position despite the pressure on EPS.
- Historical Performance Review: Over the past two years, Fresenius has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability and reliability in financial performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced no upward revisions and three downward adjustments, reflecting a cautious market outlook on the company's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FMS
Wall Street analysts forecast FMS stock price to rise
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 22.490
Low
22.00
Averages
25.00
High
28.00
Current: 22.490
Low
22.00
Averages
25.00
High
28.00
About FMS
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fresenius Medical Care Q1 Earnings Preview
- Earnings Announcement Date: Fresenius Medical Care is set to announce its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at €0.59, reflecting a significant 29.8% year-over-year decline, which could impact investor sentiment.
- Revenue Expectations: The revenue estimate for Q1 stands at €5.42 billion, representing an 11.0% year-over-year increase, indicating resilience in the company's market position despite the pressure on EPS.
- Historical Performance Review: Over the past two years, Fresenius has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability and reliability in financial performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced no upward revisions and three downward adjustments, reflecting a cautious market outlook on the company's future performance.
See More
Humacyte Regains Exclusive Rights for Symvess Outside the U.S.
- Agreement Amendment: Humacyte (HUMA) amended its agreement with Fresenius Medical Care (FMS) on April 21, regaining exclusive rights to develop and commercialize Symvess outside the U.S., marking a strategic return to the global market.
- Product Background: Symvess received FDA approval in 2024 for extremity vascular trauma, and this move allows Humacyte to directly manage product development and regulatory matters in international markets.
- Financial Arrangement: Under the amended agreement, Humacyte will pay Fresenius low-single-digit royalties on overseas net sales after a two-year royalty-free period, supporting potential revenue growth for the company.
- Market Potential: The regained rights will enable Humacyte to respond more flexibly to international market demands, particularly in the Middle East, where it recently secured a $1.48 million purchase commitment for Symvess from Saudi Arabia, further enhancing its competitive position.
See More
Focus Graphite Advances Infrastructure Development for Lac Knife Project
- Infrastructure Assessment: Focus Graphite has engaged Norda-Stelo to conduct a corridor selection and preliminary evaluation for access road and powerline infrastructure for the Lac Knife Project, with results expected by the end of May 2026, facilitating environmental baseline work and geotechnical surveys for future development phases.
- Improved Accessibility: The proposed all-season access road will link Lac Knife to the upgraded Highway 389, enhancing transportation efficiency for personnel and equipment, improving mine construction logistics, and ensuring a safer and more reliable work environment for operations.
- Funding Application Progress: The company has applied for federal and provincial infrastructure funding to support the development of the access road and powerline, aligning with government priorities for critical minerals development and northern infrastructure investment, which is expected to boost regional economic growth.
- Equity Conversion Support: Chairman Jeff York has converted C$500,000 of his loan into 1,388,889 common shares, demonstrating his ongoing commitment to the company and strengthening Focus Graphite's capital base to support future growth.
See More
Focus Graphite Launches $14.1M NRCan-Funded Program for High-Purity Graphite Production
- Program Launch: Focus Graphite has shipped a six-tonne bulk ore sample from its 100%-owned Lac Knife Graphite Project, officially commencing a NRCan-funded demonstration program aimed at producing approximately 500 kilograms of high-purity graphite concentrate to support downstream thermal purification and product validation.
- Technical Collaboration: SGS Canada will handle the crushing, blending, and metallurgical benchmarking of the sample, targeting the generation of high-grade graphite concentrate with approximately 95% graphitic carbon, with production expected to be completed and shipped to technology partner TMEC within 8 to 9 weeks.
- Strategic Importance: This initiative not only advances Canada's self-sufficiency in critical minerals but also provides essential support for downstream applications of graphite in batteries and defense, thereby strengthening national economic security.
- Future Outlook: Focus Graphite is evaluating multiple potential host facilities for the installation of its thermal purification demonstration plant, aiming to establish a complete supply chain pathway from resource to high-purity graphite product, further enhancing its competitive position in the market.
See More
Fresenius Medical Care Reports Q4 2025 Earnings and Future Outlook
- Earnings Highlights: Fresenius Medical Care reported a Q4 2025 Non-GAAP EPS of €1.44 and revenue of €5.07 billion, reflecting a slight year-over-year decline of 0.2%, indicating stability amid market fluctuations.
- Shareholder Return Plan: The proposed dividend for fiscal year 2025 is €1.49 per share, a 3% increase, representing 33% of adjusted net income, demonstrating the company's ongoing commitment to shareholders, alongside a €1.0 billion share buyback program currently underway.
- Divergent Business Performance: Care Delivery revenue decreased by 2% to €3.507 billion, but grew by 6% at constant currency, while Value-Based Care revenue surged by 32% to €637 million, reflecting success in new business areas.
- Future Outlook: Fresenius Medical Care expects revenue growth to be broadly flat in 2026, with operating income anticipated to remain in a mid-single-digit growth range, indicating a cautious approach to future growth while confirming its mid-teens operating income margin target for 2030.
See More
Fresenius Medical Care Q4 Earnings Preview
- Earnings Announcement Date: Fresenius Medical Care is set to release its Q4 2023 earnings on February 24 before market open, with consensus EPS estimate at $0.66, reflecting a 27.5% year-over-year decline, and revenue estimate at $5.72 billion, down 4.5% year-over-year.
- Historical Performance: Over the past two years, Fresenius has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, indicating a strong track record of exceeding financial forecasts and maintaining investor confidence.
- Estimate Revision Trends: In the last three months, EPS estimates saw one upward revision with no downward adjustments, while revenue estimates experienced two upward and two downward revisions, suggesting mixed market sentiment regarding the company's future performance.
- Market Confidence Issues: Despite its historical performance, there is low confidence in Fresenius Medical Care's ability to accelerate growth, which may limit potential upside in its stock price.
See More
Fresenius Medical Care Q1 Earnings Preview
- Earnings Announcement Date: Fresenius Medical Care is set to announce its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at €0.59, reflecting a significant 29.8% year-over-year decline, which could impact investor sentiment.
- Revenue Expectations: The revenue estimate for Q1 stands at €5.42 billion, representing an 11.0% year-over-year increase, indicating resilience in the company's market position despite the pressure on EPS.
- Historical Performance Review: Over the past two years, Fresenius has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability and reliability in financial performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward and one downward revision, while revenue estimates experienced no upward revisions and three downward adjustments, reflecting a cautious market outlook on the company's future performance.
See More
Humacyte Regains Exclusive Rights for Symvess Outside the U.S.
- Agreement Amendment: Humacyte (HUMA) amended its agreement with Fresenius Medical Care (FMS) on April 21, regaining exclusive rights to develop and commercialize Symvess outside the U.S., marking a strategic return to the global market.
- Product Background: Symvess received FDA approval in 2024 for extremity vascular trauma, and this move allows Humacyte to directly manage product development and regulatory matters in international markets.
- Financial Arrangement: Under the amended agreement, Humacyte will pay Fresenius low-single-digit royalties on overseas net sales after a two-year royalty-free period, supporting potential revenue growth for the company.
- Market Potential: The regained rights will enable Humacyte to respond more flexibly to international market demands, particularly in the Middle East, where it recently secured a $1.48 million purchase commitment for Symvess from Saudi Arabia, further enhancing its competitive position.
See More
Focus Graphite Advances Infrastructure Development for Lac Knife Project
- Infrastructure Assessment: Focus Graphite has engaged Norda-Stelo to conduct a corridor selection and preliminary evaluation for access road and powerline infrastructure for the Lac Knife Project, with results expected by the end of May 2026, facilitating environmental baseline work and geotechnical surveys for future development phases.
- Improved Accessibility: The proposed all-season access road will link Lac Knife to the upgraded Highway 389, enhancing transportation efficiency for personnel and equipment, improving mine construction logistics, and ensuring a safer and more reliable work environment for operations.
- Funding Application Progress: The company has applied for federal and provincial infrastructure funding to support the development of the access road and powerline, aligning with government priorities for critical minerals development and northern infrastructure investment, which is expected to boost regional economic growth.
- Equity Conversion Support: Chairman Jeff York has converted C$500,000 of his loan into 1,388,889 common shares, demonstrating his ongoing commitment to the company and strengthening Focus Graphite's capital base to support future growth.
See More
Focus Graphite Launches $14.1M NRCan-Funded Program for High-Purity Graphite Production
- Program Launch: Focus Graphite has shipped a six-tonne bulk ore sample from its 100%-owned Lac Knife Graphite Project, officially commencing a NRCan-funded demonstration program aimed at producing approximately 500 kilograms of high-purity graphite concentrate to support downstream thermal purification and product validation.
- Technical Collaboration: SGS Canada will handle the crushing, blending, and metallurgical benchmarking of the sample, targeting the generation of high-grade graphite concentrate with approximately 95% graphitic carbon, with production expected to be completed and shipped to technology partner TMEC within 8 to 9 weeks.
- Strategic Importance: This initiative not only advances Canada's self-sufficiency in critical minerals but also provides essential support for downstream applications of graphite in batteries and defense, thereby strengthening national economic security.
- Future Outlook: Focus Graphite is evaluating multiple potential host facilities for the installation of its thermal purification demonstration plant, aiming to establish a complete supply chain pathway from resource to high-purity graphite product, further enhancing its competitive position in the market.
See More
Fresenius Medical Care Reports Q4 2025 Earnings and Future Outlook
- Earnings Highlights: Fresenius Medical Care reported a Q4 2025 Non-GAAP EPS of €1.44 and revenue of €5.07 billion, reflecting a slight year-over-year decline of 0.2%, indicating stability amid market fluctuations.
- Shareholder Return Plan: The proposed dividend for fiscal year 2025 is €1.49 per share, a 3% increase, representing 33% of adjusted net income, demonstrating the company's ongoing commitment to shareholders, alongside a €1.0 billion share buyback program currently underway.
- Divergent Business Performance: Care Delivery revenue decreased by 2% to €3.507 billion, but grew by 6% at constant currency, while Value-Based Care revenue surged by 32% to €637 million, reflecting success in new business areas.
- Future Outlook: Fresenius Medical Care expects revenue growth to be broadly flat in 2026, with operating income anticipated to remain in a mid-single-digit growth range, indicating a cautious approach to future growth while confirming its mid-teens operating income margin target for 2030.
See More
Fresenius Medical Care Q4 Earnings Preview
- Earnings Announcement Date: Fresenius Medical Care is set to release its Q4 2023 earnings on February 24 before market open, with consensus EPS estimate at $0.66, reflecting a 27.5% year-over-year decline, and revenue estimate at $5.72 billion, down 4.5% year-over-year.
- Historical Performance: Over the past two years, Fresenius has beaten EPS estimates 100% of the time and revenue estimates 88% of the time, indicating a strong track record of exceeding financial forecasts and maintaining investor confidence.
- Estimate Revision Trends: In the last three months, EPS estimates saw one upward revision with no downward adjustments, while revenue estimates experienced two upward and two downward revisions, suggesting mixed market sentiment regarding the company's future performance.
- Market Confidence Issues: Despite its historical performance, there is low confidence in Fresenius Medical Care's ability to accelerate growth, which may limit potential upside in its stock price.
See More
